MedCity News September 7, 2021
Stacey Rivkin

Unleashed from restrictive norms for recruiting and interacting with patients, researchers are finding ways to bring more people into trials by simply making enrollment and participation accessible beyond restraints like geography and availability during “business hours.”

In a post-Covid world, we’re seeing a decade’s worth of reshaping within clinical trials solidify in less than a year. While the life sciences industry was making a slow build toward decentralized clinical trials and broader inclusion, Covid-19 exposed gaps in reach and efficiency that can no longer be ignored. Moving forward, industry leaders are focused on modernizing and “opening up” the model for operating clinical trials in these three categories:

  • Recruiting
  • Participating
  • Monitoring

For enterprises in the life sciences industry, the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech, Provider
Brazil’s plan for low-cost CAR-Ts
PacBio’s Repeat Expansion Panel, Owkin-Sanofi AI Take on Immunology, More
STAT+: Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful again
Moderna gets Blackstone backing for flu vaccine R&D
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Share This Article